Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions…
$2.94+4.08%
报价 2026-11-09
市值
$25.3M
EV
$31.2M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -67.9%
$2.01$9.15
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| NSRXNasus Pharma Ltd. | $25.3M | +4.1% | – | 0% | – | – | – | |
| ABVCABVC BioPharma, Inc. | $27.2M | +5.3% | +740.5% | 100% | – | – | – | |
| BYSIBeyondSpring Inc. | $25.4M | -1.4% | +41.1% | 0% | – | – | – | |
| TVGNTevogen Bio Holdings Inc. | $24.9M | +7.0% | – | 0% | – | – | – | |
| ALGSAligos Therapeutics, Inc. | $24.7M | -2.9% | +528.0% | 99.2% | – | – | – | |
| CELUCelularity Inc. | $24.7M | -0.1% | +76.0% | 19.2% | – | – | – | |
| EDSAEdesa Biotech, Inc. | $24M | +16.4% | – | 0% | – | – | – | |
| FLNAFilana Therapeutics, Inc. | $23.8M | +8.7% | – | 0% | – | – | – | |
| CVMCEL-SCI Corporation | $23.7M | -6.9% | +304.3% | 0% | – | – | – | |
| 同行中位数 | – | – | +304.3% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。